AVTX
$15.38
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States.
Recent News
Avalo Therapeutics CEO Teases Q2 Top-Line Data for AVTX-009 Phase 2b HS LOTUS Trial at Conference
Avalo Therapeutics (NASDAQ:AVTX) CEO Garry Neil said the company expects to report top-line data in the second quarter from its completed Phase 2b LOTUS trial of AVTX-009 in hidradenitis suppurativa (HS), outlining what he described as operational execution milestones in 2025 and the rationale for t
Avalo Therapeutics Highlights AVTX-009 Plan, Near-Term Phase II HS Data at Healthcare Conference
Avalo Therapeutics (NASDAQ:AVTX) used a presentation at its 46th Annual Healthcare Conference appearance to outline its strategy for AVTX-009, a high-affinity human monoclonal antibody designed to neutralize interleukin-1 beta (IL-1β), and to discuss how upcoming Phase II data in hidradenitis suppur
Avalo Therapeutics Highlights AVTX-009 HS Phase II Catalyst, Cash Runway at Oppenheimer Conference
Avalo Therapeutics (NASDAQ:AVTX) Chief Executive Officer Dr. Garry Neil discussed the company’s hidradenitis suppurativa (HS) program and upcoming clinical catalyst during a fireside chat at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference. The discussion focused on Avalo’s lead candida
Avalo Therapeutics Eyes Q2 2026 Phase IIb LOTUS Readout for AVTX-009 in Hidradenitis Suppurativa
Avalo Therapeutics (NASDAQ:AVTX) is preparing to report phase IIb data in the second quarter of 2026 from its LOTUS trial evaluating AVTX-009 in hidradenitis suppurativa (HS), CEO Garry Neil said during a fireside chat at Guggenheim’s Emerging Outlook Biotech Summit 2026. Neil described LOTUS as a
Piper Sandler Maintains Bullish $48 Price Target on Avalo Therapeutics (AVTX)
Avalo Therapeutics, Inc. (NASDAQ:AVTX) is one of the top long-term biotechnology stocks to buy. On October 17, Piper Sandler analyst Yasmeen Rahimi reaffirmed her Buy rating on Avalo Therapeutics Inc. (NASDAQ:AVTX), maintaining a price target of $48, which implies a substantial upside potential of 167.86% from the stock’s current trading levels. The buy stance underscores […]